Modified colloids and their use

Die Erfindung betrifft an Kolloide gebundene Arzneiwirkstoffe, ein Verfahren zu deren Herstellung, deren Verwendung zur direkten Injektion sowie Zellsuspensionen umfassend diese an Kolloide gebundenen Arzneiwirkstoffe in phagozytierter Form und deren Verwendung für den gezielten Arzneistofftransport an bestimmte Wirkorte des menschlichen und tierischen Körpers. Die Erfindung betrifft ferner ein Kit-of-parts umfassend die Einzelbestandteile zur Herstellung der wässrigen pharmazeutischen Zusammensetzungen. In einer weiteren Ausgestaltung betrifft die Erfindung durch Kolloide modifizierte Kolloide und deren Verwendung als Blutplasmaersatzmittel. Colloid-bonded drugs (I) and colloid-modified colloids (II) are new. Modified colloids of formulae Mn-X-(L-Z)m (I) and Mn-X-(L-E)m (II) are new. X, E = colloidal compounds; Z = medicinally active agent Z; L = linker covalently bonded to X and Y (preferably a functional group selected from carboxylate ester, carboxamide and ester); M = fluorescent label; m = 1-10000; n = 0 or 1. Independent claims are also included for: (1) aqueous pharmaceutical compositions containing (I); (2) kits comprising the composition in (1) and a vessel suitable for centrifugation, in spatially separated form; (3) a cell suspension comprising blood cells containing (I); (4) the preparation of the cell suspension by: ex vivo incubation of human or animal blood with (I), by mixing an aqueous composition containing (I) with the blood; (i) separating incubated blood cells (preferably leukocytes) from the aqueous medium by centrifugation; (ii) removing non-absorbed (I) from the blood cells by dialysis; and (iii) isolating the cell suspension containing the incubated blood cells; (5) the use of the cell suspension for the preparation of a medicament for the targeted uptake of the drug Z in specific organs of the human body; (6) aqueous pharmaceutical compositions containing (II); and (7) blood plasma substitutes comprising (II) in aqueous solution.